𝔖 Bobbio Scriptorium
✦   LIBER   ✦

MR imaging of soft-tissue masses: Role of gadopentetate dimeglumine

✍ Scribed by Richard A. Benedikt; James S. Jelinek; Mark J. Kransdorf; Richard P. Moser; B. Hudson Berrey


Publisher
John Wiley and Sons
Year
1994
Tongue
English
Weight
776 KB
Volume
4
Category
Article
ISSN
1053-1807

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

To assess the effectiveness of gadopentetate dimeglumine in the magnetic resonance (MR) imaging evaluation of soft‐tissue masses without osseous involvement, 30 patients underwent MR imaging before and after administration of contrast material (0.1 mmol/ kg) of the 30 lesions, 22 were benign and eight were malignant; histologic confirmation was available in all lesions except one benign lesion. Overall, enhancement was detected in 26 (87%) of 30 lesions: 18 (82%) of the 22 benign lesions and eight (100%) of eight malignant lesions. Enhancement was characterized as homogeneous (two [11%] benign lesions, two [25%] malignant lesions), inhomogeneous (11 [61%] benign lesions, six [75%] malignant lesions), or peripheral (five [28%] benign lesions, no malignant lesions) of the 19 lesions assessed for a change in enhancement over time, seven (37%) showed an increase and two (11%) showed a decrease in signal intensity. The authors conclude that benign and malignant soft‐tissue lesions could not be differentiated solely on the basis of enhancement (pattern, degree, or time course).


📜 SIMILAR VOLUMES


MR imaging of Hippel-Lindau disease: Val
✍ David R. Nelson; William T. C. Yuh; Mary H. Wazirim; Tony J. Ryals; Yutaka Sato; 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 749 KB

## Abstract Hippel‐Lindau disease is an autosomal dominant disorder characterized by tumors of the central nervous system and abdominal viscera. Frequent multisystem radiologic evaluation of persons at risk is desirable. Twenty‐seven patients with Hippel‐Lindau disease or a family history of the di

Measurement of renal transit of gadopent
✍ Gerald L. Wolf; Bernard Hoop; John A. Cannillo; Jadwiga A. Rogowska; Elkan F. Ha 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 979 KB

## Abstract Times of peak gadolinium concentration ([Gd]) after intravenous (IV) and left ventricular (LV) bolus injection of gadopentetate dimeglumine were determined in renal cortex and medulla in normal rabbits and in rabbits after saline load (overhydration) or hemorrhage (dehydration). Magneti

Chronic pancreatitis: MR imaging feature
✍ Richard C. Semelka; J. Patrick Shoenut; Mervyn A. Kroeker; Allan B. Micflikier 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 499 KB

## Abstract Magnetic resonance (MR) imaging was performed in patients with a history (>1 year) of inflammatory pancreatic disease. Calcification was seen at recent computed tomographic examinations in 13 patients and was not seen in nine patients. On fat‐suppressed spin‐echo images, the signal‐to‐n

Improved cine MR imaging of left ventric
✍ Dudley J. Pennell; S. Richard Underwood; Donald B. Longmore 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 634 KB

## Abstract The assessment of left ventricular wall motion with cine magnetic resonance imaging in the cardiac long axes is useful; however, image quality is limited by reduced signal intensity due to saturation of blood flowing predominantly in plane. Twenty subjects were studied to evaluate the e

Diagnostic value of gadopentetate dimegl
✍ Richard E. Rosenthal; Paul Wozney 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 496 KB

## Abstract Three magnetic resonance (MR) imaging techniques (T1‐weighted, T2‐weighted, and T1‐weighted gadopentetate dimeglumine—enhanced) were compared in 32 consecutive MR imaging studies of 26 patients with suspected musculoskeletal masses. T2‐weighted images were superior to T1‐weighted enhanc

Effect on fetal mouse development of exp
✍ Neil M. Rofsky; Donald J. Pizzarello; Jeffrey C. Weinreb; Michael M. Ambrosino; 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 339 KB

## Abstract Pregnant mice were exposed to one of five regimens at 9.5 days of gestation: no treatment (group 1), intraperitoneal injection of normal saline (group 2), intraperitoneal injection of gadopentetate dimeglumine (group 3), intraperitoneal injection of gadopentetate dimeglumine and magneti